Drug related problem hospitalization in the Requena General Hospital (1997-2000);Ingresos hospitalarios por problems relacionados con la medicación en el hospital general de Requena (1997-2000)

Pharmaceutical Care Espana

Volumn 4, Issue 5, 2002, Pages 286-299

  Marco, José Luis ^a   Boscá, Beatriz ^a   San Martín, Maria Dolores ^a   Borrás, Joaquín ^a   Díez Martínez, Ana ^a  

^a HOSPITAL GENERAL DE REQUENA   (Spain)

Author keywords

Adverse drug reactions; Hospital admission due to drug related problem (HA DRP); Latrogenia

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; BENZODIAZEPINE DERIVATIVE; CALMANTE VITAMINADO; CITALOPRAM; CLARITHROMYCIN; CORTICOSTEROID; COULDINA; DICLOFENAC; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; IBUPROFEN; INYESPRIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; RAMIPRIL; RESERPINE; SPIRONOLACTONE; TIMOLOL MALEATE;

ACCIDENT; ARTICLE; CONTROLLED STUDY; DIGESTIVE SYSTEM HEMORRHAGE; DISEASE CLASSIFICATION; DRUG INDUCED DISEASE; DRUG INTOXICATION; DRUG OVERDOSE; DRUG SAFETY; DRUG USE; GENERAL HOSPITAL; GENERAL PRACTITIONER; HEALTH PROGRAM; HOSPITAL ADMISSION; HOSPITAL SERVICE; HOSPITALIZATION; HUMAN; MEDICAL RECORD; PHARMACIST; PHYSICIAN; SPAIN; SUICIDE ATTEMPT;

EID: 0036757925     PISSN: 11396202     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Consenso de Granada sobre Problemas Relacionados con los Medicamentos. Pharm Care Esp. 1999; 1:107- 112.
2. Strand LM, Morley CP, Cipolle RJ, Ramsey R, Lamsam GD. Problemas relacionados con medicamentos: su estructura y función. Pharm Care Esp 1999; 1:127-132.
3. Planells C, Rodríguez Sasiaín JM, Jiménez Torres N. Reacciones adversas a medicamentos que motivan la admisión hospitalaria detectadas mediante el diagnóstico de ingreso. Farm Hosp 1993; 17: 133-43.
4. Abajo FJ, Frías J, Lopo CR, et al. Las reacciones adversas a medicamentos como un motivo de consulta al servicio de urgencias de un hospital general. Med Clin 1989; 92:530-535.
5. aV, et al. Revisión retrospectiva de historias clínicas como método de farmacovigilancia en un hospital comarcol. Farm Hosp 1993; 17: 179-188.
6. Jue SG, Clark BG, Araki MA. Inservice teaching and adverse drug reactions in a nursing home. Drug intell Clin Pharm 1985; 19:483-487.
7. Swan GT, Jones AN, Hughes JD, et al. Adverse drug reactions: A systematic approach to documentation and reproting in hospitals. Aust J Hosp Pharm 1983; 13:137-41.
8. Michel DJ, Knodel LC. Program Coordinated by a drug information service to improve adverse drug reaction reporting in a hospital. Am J Hosp Pharm 1986; 43:2202-5.
9. Lanas A, Lorente S. Prevención de la gastropatía, por AINEs. Medicine 1999; 7(119): 5587-5593.
10. Lanas A, Arroyo MT. Fármacos antisecretores y profilaxis de los efectos secundarios gastrointestinales graves asociados al consumo de AINEs. Med Clin (Barc) 2000; 114(supl2):57-62.
11. García LA, Lick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non steroidal antiinflamatory drugs. Lancet 1994; 769-772.
12. Metola M, Orueta R, Rodríguez J. Situación actual de la prevención de la gastropatía por AINE. Medifam 1999; 9:280-289.
13. Zfass AM McHenry L Jr,Sanyal AJ. Nonsteroidal antiinflamatory drug-induced gastroduodenal lesions: prophylaxis and treatment. Gastroenterologist 1993; 1:165-169.
14. Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract: The double-edged sword. Arthritis Rheum 1995; 38:5-18.
15. Griffin MR, Piper JM, Dougherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114: 257-263.
16. Ettinger B, Pressman A, Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care 1998; 4: 1377- 1382.
17. Hawkey CJ, Hudson N. Mucosol injury caused by drugs, chemicals, and stress. In Hubrich WS, Schaffner F, Berk JE (eds): Bockus Gastroenterology, ed 5. Philadelphia, WB Saunders, 1995, pp 656-699.
18. Waldorff S, et al. Amiloride-induced changes in digoxin dynamics and kinetics: abolition of digoxin-induced inotropism with amiloride, Clin Pharmacol Ther 1981; 30:172.
19. Moysey JO, et al. Amiodarone increases plasma digoxin concentrations. BMJ 1981; 282: 272.
20. Achilli A, Serra N. Amiodarone increase plasma digoxin concentrations. BMJ 1981; 282: 1630.
21. Mc Govern B, et al. Sinus arrest during treatment with amiodarone. BMJ 1982;284:160.
22. aEd. 1985. pg 134.
23. Dick H, et al. Reserpine-digitalis toxicity. Arch Intern Med 1962; 109:503.
24. Andrejak M, Hary L, Andrejak MT, et al. Diltiazem increases steady state digoxin serum levels in patients with cardiac disease. J Clin Pharmacol 1987; 27: 967-970.
25. Sánchez B, Muruzabal MJ, Peralta G, et al. Clarithromycin-oral anticoagulants interactions: report of five cases. Clin Drug Invest 1997; 13: 220-222.
26. Richard C, Riou B, Berdeaux A, et al. Prospective study of the potentiation of acenocoumarol by amiodarone. Eur J Clin Pharmacol 1985; 28:625-629.
27. Armayor GM, López LM. Lisinopril: a new angiotensin-converting enzyme inhibitor. Drug Intell Clin Pharm 1988; 22:365-372.
28. Burnakis TG, Moiduch HJ. Combined therapy with captopril and potassium supplementation. A potential for hyperkalemia. Arch Intern Med 1984; 144:2371-2372.
29. Borrás-Blasco J, Marco-Garbayo JL, Boscá-Sanleon B, Navorro-Ruiz A. Probable interaction between acenocoumarol citalopram. Ann Pharmacother 2001 aceptado para su publicación (en prensa).